1
Tübingen/New York-The Tübingen biotech company Curevac and his partner GSK have included their patent dispute with Pfizer and Biontech for mRNA technology in COVID-19 vaccines. This was announced by Curevac on Thursday. The agreement provides for a total of $ 740 million of Curevac and GSK. In addition, the two companies will receive license fees in the single-digit percentage range on the sale of COVID 19 vaccines in the United States.
